EU/3/16/1643

About

On 28 April 2016, orphan designation (EU/3/16/1643) was granted by the European Commission to Cytori Ltd, United Kingdom, for autologous stromal vascular cell fraction from adipose tissue for the treatment of systemic sclerosis.

The sponsorship was transferred to Clinical Network Services (NL) B.V., Netherlanks, in March 2019.

In August 2020, Clinical Network Services (NL) B.V. changed name to Scendea (NL) B.V.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in August 2020 on request of the Sponsor.

In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.

Key facts

Active substance
Autologous stromal vascular cell fraction from adipose tissue
Disease / condition
Treatment of systemic sclerosis
Date of first decision
28/04/2016
Outcome
Withdrawn
EU designation number
EU/3/16/1643

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

De Cuserstraat 93
1081 CN Amsterdam
Noord-Holland
The Netherlands
Tel. +31 2089 49169
E-mail: orphan@scendea.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating